Primary Care POC Diagnostics Market Report 2026

The primary care poc diagnostics market size has grown strongly in recent years. It will grow from $17.38 billion in 2025 to $18.59 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing prevalence of infectious and chronic diseases, wider adoption of glucose and cardiometabolic testing, expansion of primary care diagnostic capabilities, increased use of otc diagnostic products, improved accessibility of rapid tests.

The primary care poc diagnostics market size is expected to see strong growth in the next few years. It will grow to $24.6 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing demand for decentralized diagnostics, rising integration of ai-enabled diagnostics, expansion of telehealth-supported testing, growing focus on preventive screening, increasing investments in personalized diagnostics. Major trends in the forecast period include increasing adoption of rapid diagnostic testing, growing integration of digital poc devices, rising demand for home-use diagnostic kits, expansion of multiplex testing platforms, enhanced focus on early disease detection.

The rising prevalence of infectious diseases is expected to propel the growth of the primary care point-of-care diagnostics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, and they can spread directly or indirectly through contact with contaminated surfaces, air, water, or vectors such as insects. The increasing occurrence of infectious diseases is attributed to factors including poor environmental conditions, rapid urbanization, antimicrobial resistance, and insufficient vaccination coverage. Primary care point-of-care diagnostics play a crucial role in addressing infectious diseases by enabling early detection, prompt treatment, and effective disease control across a range of healthcare settings. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal agency, tuberculosis cases increased from 9,622 in 2023 to 10,347 in 2024, representing an 8% rise, while the incidence rate grew from 2.9 to 3 per 100,000 population, a 6% increase. Therefore, the growing prevalence of infectious diseases is driving the expansion of the primary care point-of-care diagnostics market.

Major companies operating in the primary care point-of-care diagnostics market are concentrating on the development of advanced technologies such as microfluidic-based rapid susceptibility testing to support faster and more accurate antibiotic decision-making. Microfluidic rapid susceptibility testing utilizes miniature fluid channels to quickly isolate and grow bacteria, allowing early assessment of their response to different antimicrobial agents and significantly reducing result turnaround times. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostic solutions company, launched the PA-100 AST System incorporating proprietary microfluidic technology. The system is capable of detecting bacteria from urine samples in approximately 15 minutes and providing antimicrobial susceptibility test results within about 30 minutes during the initial clinic visit. The compact, desktop-sized analyzer operates with reagent cartridges that accept samples directly for automated analysis and can be easily used by healthcare professionals without specialized laboratory training. By accelerating diagnostic processes, the system supports appropriate antimicrobial use during first patient visits and contributes to efforts to combat antimicrobial resistance.

In July 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired LumiraDx’s point-of-care technology from LumiraDx for $350 million. Through this acquisition, Roche aims to broaden its diagnostic portfolio and enhance access to decentralized testing solutions, particularly within primary care environments and in low- to middle-income countries. LumiraDx is a UK-based point-of-care diagnostics company focused on advancing community-based healthcare delivery.

Major companies operating in the primary care poc diagnostics market are Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson And Company, bioMerieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Nova Biomedical Corporation, Randox Laboratories Ltd, Ortho Clinical Diagnostics, Nipro Corporation, OraSure Technologies, Meridian Bioscience Inc, DiaSorin SpA, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Fujirebio Diagnostics Inc., Immunodiagnostic Systems Holdings PLC, Quotient Limited, AccuBioTech Co. Ltd., bioMedomics Inc.

North America was the largest region in the primary care POC diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary care poc diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary care poc diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the primary care POC diagnostics market by increasing costs of imported reagents, biosensors, electronic components, microfluidic cartridges, and diagnostic analyzers used across rapid testing platforms. Hospitals, clinics, and diagnostic centers in North America and Europe are most affected due to reliance on imported diagnostic consumables, while Asia-Pacific faces pricing pressure on export-oriented device manufacturing. These tariffs are raising procurement costs and slowing adoption in cost-sensitive primary care settings. However, they are also encouraging local manufacturing of test kits, regional sourcing of consumables, and innovation in cost-effective point-of-care diagnostic solutions.

The primary care poc diagnostics market research report is one of a series of new reports that provides primary care poc diagnostics market statistics, including primary care poc diagnostics industry global market size, regional shares, competitors with a primary care poc diagnostics market share, detailed primary care poc diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the primary care poc diagnostics industry. This primary care poc diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary care point-of-care diagnostics refer to medical tests or assessments that are conducted quickly and conveniently within a primary care environment, such as a physician’s office or clinic, without the need for specialized equipment or extensive laboratory processing. These diagnostics are designed to deliver rapid results, enabling healthcare providers to make prompt and informed clinical decisions during the initial patient visit.

The main product categories in primary care point-of-care diagnostics include glucose monitoring, cardiometabolic testing products, infectious disease testing products, coagulation testing products, pregnancy and fertility testing products, tumor or cancer marker testing products, cholesterol testing products, hematology testing products, drug-of-abuse testing products, and others. Glucose monitoring involves measuring blood glucose levels to support diabetes management. These diagnostics are available through prescription-based and over-the-counter testing formats and are used across various settings such as hospitals, diagnostic centers, research laboratories, home-care environments, and other end uses.

The primary care POC diagnostics market consists of sales of respiratory pathogen testing products, thyroid function testing products, electrolyte testing products, and liver function testing products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.